中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 4
Apr.  2022
Turn off MathJax
Article Contents

Mechanism of action of nucleotide-binding oligomerization domain-like receptor protein 3 inflammasome in liver diseases

DOI: 10.3969/j.issn.1001-5256.2022.04.041
Research funding:

National Natural Science Foundation of China (8193000309);

Sichuan Provincial Department of Science and Technology Project (2021YFH0150);

Sichuan Administration of Traditional Chinese Medicine Project (2017C012)

More Information
  • Corresponding author: BAI Zhaofang, baizf2008@hotmail.com(ORCID: 0000-0002-6208-150X); SUN Qin, zxyjhsq@swmu.edu.cn(ORCID: 0000-0002-4624-8808)
  • Received Date: 2021-08-25
  • Accepted Date: 2021-09-26
  • Published Date: 2022-04-20
  • Inflammasomes play an important role in the innate immunity of the liver; however, the excessive activation of inflammasomes can lead to liver inflammation and injury. The mechanism of nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome-mediated liver injury has been extensively studied. Related studies have shown that the development of various liver diseases may be associated with the excessive activation of inflammasomes, especially NLRP3 inflammasome. This article reviews inflammasomes, the activation mechanism of NLRP3 inflammasome, and the role of NLRP3 inflammasome in different liver diseases, so as to provide a reference for the treatment targets of liver diseases from the perspective of NLRP3 inflammasome.

     

  • loading
  • [1]
    TAKEUCHI O, AKIRA S. Pattern recognition receptors and inflammation[J]. Cell, 2010, 140(6): 805-820. DOI: 10.1016/j.cell.2010.01.022.
    [2]
    STOREK KM, MONACK DM. Bacterial recognition pathways that lead to inflammasome activation[J]. Immunol Rev, 2015, 265(1): 112-129. DOI: 10.1111/imr.12289.
    [3]
    LUAN J, JU D. Inflammasome: A double-edged sword in liver diseases[J]. Front Immunol, 2018, 9: 2201. DOI: 10.3389/fimmu.2018.02201.
    [4]
    HE Y, HARA H, NÚÑEZ G. Mechanism and regulation of NLRP3 inflammasome activation[J]. Trends Biochem Sci, 2016, 41(12): 1012-1021. DOI: 10.1016/j.tibs.2016.09.002.
    [5]
    MALTEZ VI, TUBBS AL, COOK KD, et al. Inflammasomes coordinate pyroptosis and natural killer cell cytotoxicity to clear infection by a ubiquitous environmental bacterium[J]. Immunity, 2015, 43(5): 987-997. DOI: 10.1016/j.immuni.2015.10.010.
    [6]
    HENAO-MEJIA J, ELINAV E, JIN C, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity[J]. Nature, 2012, 482(7384): 179-185. DOI: 10.1038/nature10809.
    [7]
    HAGA H, YAN IK, BORRELLI DA, et al. Extracellular vesicles from bone marrow-derived mesenchymal stem cells protect against murine hepatic ischemia/reperfusion injury[J]. Liver Transpl, 2017, 23(6): 791-803. DOI: 10.1002/lt.24770.
    [8]
    SUN Q, LOUGHRAN P, SHAPIRO R, et al. Redox-dependent regulation of hepatocyte absent in melanoma 2 inflammasome activation in sterile liver injury in mice[J]. Hepatology, 2017, 65(1): 253-268. DOI: 10.1002/hep.28893.
    [9]
    SINGH S, JHA S. NLRs as Helpline in the Brain: mechanisms and therapeutic implications[J]. Mol Neurobiol, 2018, 55(10): 8154-8178. DOI: 10.1007/s12035-018-0957-4.
    [10]
    ELLIOTT EI, SUTTERWALA FS. Initiation and perpetuation of NLRP3 inflammasome activation and assembly[J]. Immunol Rev, 2015, 265(1): 35-52. DOI: 10.1111/imr.12286.
    [11]
    EVAVOLD CL, RUAN J, TAN Y, et al. The pore-forming protein gasdermin D regulates interleukin-1 secretion from living macrophages[J]. Immunity, 2018, 48(1): 35-44. e6. DOI: 10.1016/j.immuni.2017.11.013.
    [12]
    MCRAE S, IQBAL J, SARKAR-DUTTA M, et al. The hepatitis C virus-induced NLRP3 inflammasome activates the sterol regulatory element-binding protein (SREBP) and regulates lipid metabolism[J]. J Biol Chem, 2016, 291(7): 3254-3267. DOI: 10.1074/jbc.M115.694059.
    [13]
    Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013[J]. Lancet, 2015, 386(9995): 743-800. DOI: 10.1016/S0140-6736(15)60692-4.
    [14]
    JIA Y, MA L, WANG Y, et al. NLRP3 inflammasome and related cytokines reflect the immune status of patients with HBV-ACLF[J]. Mol Immunol, 2020, 120: 179-186. DOI: 10.1016/j.molimm.2020.01.011.
    [15]
    TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800.
    [16]
    XIE WH, DING J, XIE XX, et al. Hepatitis B virus X protein promotes liver cell pyroptosis under oxidative stress through NLRP3 inflammasome activation[J]. Inflamm Res, 2020, 69(7): 683-696. DOI: 10.1007/s00011-020-01351-z.
    [17]
    MOLYVDAS A, GEORGOPOULOU U, LAZARIDIS N, et al. The role of the NLRP3 inflammasome and the activation of IL-1β in the pathogenesis of chronic viral hepatic inflammation[J]. Cytokine, 2018, 110: 389-396. DOI: 10.1016/j.cyto.2018.04.032.
    [18]
    YU X, LAN P, HOU X, et al. HBV inhibits LPS-induced NLRP3 inflammasome activation and IL-1β production via suppressing the NF-κB pathway and ROS production[J]. J Hepatol, 2017, 66(4): 693-702. DOI: 10.1016/j.jhep.2016.12.018.
    [19]
    CHEN H, HE G, CHEN Y, et al. Differential activation of NLRP3, AIM2, and IFI16 inflammasomes in humans with acute and chronic hepatitis B[J]. Viral Immunol, 2018, 31(9): 639-645. DOI: 10.1089/vim.2018.0058.
    [20]
    GAO B, BATALLER R. Alcoholic liver disease: Pathogenesis and new therapeutic targets[J]. Gastroenterology, 2011, 141(5): 1572-1585. DOI: 10.1053/j.gastro.2011.09.002.
    [21]
    PETRASEK J, BALA S, CSAK T, et al. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice[J]. J Clin Invest, 2012, 122(10): 3476-3489. DOI: 10.1172/JCI60777.
    [22]
    CUI K, YAN G, XU C, et al. Invariant NKT cells promote alcohol-induced steatohepatitis through interleukin-1β in mice[J]. J Hepatol, 2015, 62(6): 1311-1318. DOI: 10.1016/j.jhep.2014.12.027.
    [23]
    WREE A, EGUCHI A, MCGEOUGH MD, et al. NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice[J]. Hepatology, 2014, 59(3): 898-910. DOI: 10.1002/hep.26592.
    [24]
    KHANOVA E, WU R, WANG W, et al. Pyroptosis by caspase11/4-gasdermin-D pathway in alcoholic hepatitis in mice and patients[J]. Hepatology, 2018, 67(5): 1737-1753. DOI: 10.1002/hep.29645.
    [25]
    SUZUKI A, DIEHL AM. Nonalcoholic steatohepatitis[J]. Annu Rev Med, 2017, 68: 85-98. DOI: 10.1146/annurev-med-051215-031109.
    [26]
    MARRA F, SVEGLIATI-BARONI G. Lipotoxicity and the gut-liver axis in NASH pathogenesis[J]. J Hepatol, 2018, 68(2): 280-295. DOI: 10.1016/j.jhep.2017.11.014.
    [27]
    JINDAL A, BRUZZÌ S, SUTTI S, et al. Fat-laden macrophages modulate lobular inflammation in nonalcoholic steatohepatitis (NASH)[J]. Exp Mol Pathol, 2015, 99(1): 155-162. DOI: 10.1016/j.yexmp.2015.06.015.
    [28]
    PIERANTONELLI I, RYCHLICKI C, AGOSTINELLI L, et al. Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD[J]. Sci Rep, 2017, 7(1): 12200. DOI: 10.1038/s41598-017-11744-6.
    [29]
    QI Y, DU X, YAO X, et al. Vildagliptin inhibits high free fatty acid (FFA)-induced NLRP3 inflammasome activation in endothelial cells[J]. Artif Cells Nanomed Biotechnol, 2019, 47(1): 1067-1074. DOI: 10.1080/21691401.2019.1578783.
    [30]
    XU B, JIANG M, CHU Y, et al. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice[J]. J Hepatol, 2018, 68(4): 773-782. DOI: 10.1016/j.jhep.2017.11.040.
    [31]
    ROSSATO M, DI VINCENZO A, PAGANO C, et al. The P2X7 Receptor and NLRP3 axis in non-alcoholic fatty liver disease: A brief review[J]. Cells, 2020, 9(4): 1047. DOI: 10.3390/cells9041047.
    [32]
    BAEZA-RAJA B, GOODYEAR A, LIU X, et al. Pharmacological inhibition of P2RX7 ameliorates liver injury by reducing inflammation and fibrosis[J]. PLoS One, 2020, 15(6): e0234038. DOI: 10.1371/journal.pone.0234038.
    [33]
    WU M. Study on the mechanism of paclitaxel based on NLRP3 inflammasome in regulation of non-alcoholic fatty liver disease under acute alcohol stimulation[D]. Yanji: Yanbian University, 2020.

    吴梅. 紫杉叶素基于NLRP3炎症小体调控急性酒精刺激下的非酒精性脂肪肝的机制研究[D]. 延吉: 延边大学, 2020.
    [34]
    HAN CY, RHO HS, KIM A, et al. FXR Inhibits endoplasmic reticulum stress-induced NLRP3 inflammasome in hepatocytes and ameliorates liver injury[J]. Cell Rep, 2018, 24(11): 2985-2999. DOI: 10.1016/j.celrep.2018.07.068.
    [35]
    MANDREKAR P, AMBADE A, LIM A, et al. An essential role for monocyte chemoattractant protein-1 in alcoholic liver injury: regulation of proinflammatory cytokines and hepatic steatosis in mice[J]. Hepatology, 2011, 54(6): 2185-2197. DOI: 10.1002/hep.24599.
    [36]
    ROBERT S, GICQUEL T, BODIN A, et al. Characterization of the MMP/TIMP imbalance and collagen production induced by IL-1β or TNF-α release from human hepatic stellate cells[J]. PLoS One, 2016, 11(4): e0153118. DOI: 10.1371/journal.pone.0153118.
    [37]
    PÉREZ-CABEZA DE VACA R, DOMÍNGUEZ-LÓPEZ M, GUERRERO-CELIS N, et al. Inflammation is regulated by the adenosine derivative molecule, IFC-305, during reversion of cirrhosis in a CCl4 rat model[J]. Int Immunopharmacol, 2018, 54: 12-23. DOI: 10.1016/j.intimp.2017.10.019.
    [38]
    KOLB R, LIU GH, JANOWSKI AM, et al. Inflammasomes in cancer: A double-edged sword[J]. Protein Cell, 2014, 5(1): 12-20. DOI: 10.1007/s13238-013-0001-4.
    [39]
    ERSHAID N, SHARON Y, DORON H, et al. NLRP3 inflammasome in fibroblasts links tissue damage with inflammation in breast cancer progression and metastasis[J]. Nat Commun, 2019, 10(1): 4375. DOI: 10.1038/s41467-019-12370-8.
    [40]
    HAMARSHEH S, ZEISER R. NLRP3 inflammasome activation in cancer: A double-edged sword[J]. Front Immunol, 2020, 11: 1444. DOI: 10.3389/fimmu.2020.01444.
    [41]
    KARKI R, MAN SM, KANNEGANTI TD. Inflammasomes and cancer[J]. Cancer Immunol Res, 2017, 5(2): 94-99. DOI: 10.1158/2326-6066.CIR-16-0269.
    [42]
    YUAN Z, HASNAT M, LIANG P, et al. The role of inflammasome activation in Triptolide-induced acute liver toxicity[J]. Int Immunopharmacol, 2019, 75: 105754. DOI: 10.1016/j.intimp.2019.105754.
    [43]
    WANG Z, XU G, ZHAN X, et al. Carbamazepine promotes specific stimuli-induced NLRP3 inflammasome activation and causes idiosyncratic liver injury in mice[J]. Arch Toxicol, 2019, 93(12): 3585-3599. DOI: 10.1007/s00204-019-02606-3.
    [44]
    GAO Y, XU G, MA L, et al. Icariside I specifically facilitates ATP or nigericin-induced NLRP3 inflammasome activation and causes idiosyncratic hepatotoxicity[J]. Cell Commun Signal, 2021, 19(1): 13. DOI: 10.1186/s12964-020-00647-1.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(1)

    Article Metrics

    Article views (658) PDF downloads(40) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return